MASS · 908 Devices Inc.

Revenue increased 13.6% year-over-year to $13.4 million in Q1 FY2026 from $11.8 million, primarily driven by sales of handheld devices as the company's financial performance continues to be impacted by device sales rates. This top-line growth reflects ongoing momentum in core product lines amid strategic focus on mass spectrometry and FTIR technologies.

Gross profit expanded 24.2% to $6.9 million, achieving a 51.4% margin versus prior periods, due to higher sales volumes, improved production efficiencies, and scale benefits. Management notes intent to leverage design, engineering, and manufacturing capabilities to further reduce costs and enhance margins long-term as unit costs decrease with volume. The company expects gross margins for products and services to improve over time through these efficiencies, supporting sustained profitability as production scales.

Operating loss deepened 16.9% to -$12.9M from -$11.0M, with operating margin at -96.3%. This widening reflects volatility in contingent consideration fair value, primarily tied to the increase in the company's publicly quoted share price during the quarter and, to a lesser extent, higher FTIR revenue projections. Such non-cash charges offset underlying operational improvements, consistent with ongoing restructuring efforts.

Net loss stood at -$12.0M or -$0.32 diluted EPS, versus $43.6M profit and $1.23 EPS last year—a 127.4% decline attributable to the prior period's discontinued operations gain. This shift underscores focus on continuing operations amid transformation, with selling, general, and administrative expenses plus amortization expected to stabilize as restructuring progresses.

Overall, Q1 demonstrates revenue and margin traction from device sales and cost discipline, tempered by non-operating volatility. Future performance hinges on handheld device adoption, manufacturing scale, and strategic execution to convert growth into profitability.